Drug intelligence / Profile preview

FCN-207

Development stage: Phase 1
Lead developer: Fochon Biosciences
Modality: Small Molecules
Administration: Oral

Overview

FCN-207 is a **high-affinity, selective inhibitor** of uric acid transporter 1 (**URAT1**), developed as a **small molecule** drug intended for the treatment of hyperuricemia and gout. By inhibiting URAT1 activity in proximal renal tubules, FCN-207 reduces the reabsorption of uric acid in the kidney, leading to **lower serum uric acid concentrations**. This investigational drug is being developed and trialed by Fochon Pharmaceuticals, a subsidiary of Shanghai Fosun Pharmaceutical (Fosun Pharma), with studies conducted both in China and globally. Clinical trials have focused on establishing safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers[1][2][3][4].

Other names: FCN-207FCN207FCN 207

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on FCN-207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCN-207.

Explore the full profile